Thermo Fisher Bioproduction Insights

  1. 3 Innovations For Reducing Risk In Continuous Downstream Bioprocessing 4/21/2026

    Batch-to-continuous transitions in downstream bioprocessing carry real risks. Here's how advanced analytics, smarter buffer strategies, and single-use systems are changing that calculus.

  2. What To Look For In A Cell Culture Media Supplier 4/17/2026

    Choosing a cell culture media supplier is crucial in biopharmaceutical manufacturing. Explore five key factors to take into account when choosing a supplier and evaluating their capabilities.

  3. Criteria For Effective Bioprocess Scale-Up 3/25/2026

    Discover four essential bioprocess scale-up criteria and how each balances hydrodynamics, shear, and mass transfer across manufacturing scales.

  4. Demonstrating Bioprocess Scalability Through Platform Consistency 3/25/2026

    Explore how a unified bioreactor design enables consistent process performance from bench to production, minimizing scale-up risk while maintaining cell growth and yield.

  5. How Predictive Algorithms Will Redefine Cell Culture Media Development 3/25/2026

    Discover how predictive modeling and AI are reshaping cell culture media development in biopharmaceutical manufacturing — accelerating timelines and enabling smarter, data-driven formulation strategies.

  6. Titer Analysis In The Era Of Complex Antibody Therapeutics 3/13/2026

    As antibody formats grow more complex, titer is harder to measure. Chromatography cuts through matrix noise to deliver accurate, scalable quantification from early development through QC.

  7. The Future Of RNA Manufacturing Starts With Raw Material Innovation 2/11/2026

    Amid the mRNA and oligonucleotide therapeutic boom, sponsors and manufacturers are exploring how to make critical raw materials—capping agents, lipid nanoparticles, and RNA polymerase—more effective.

  8. Reframing Residual DNA Testing: What It Is--And What It Isn't 2/11/2026

    Residual host-cell DNA quantitation requires sensitive, well-validated analytical workflows to ensure accurate impurity control, process understanding, and regulatory compliance in complex biologics.

  9. Activate Advanced Contamination Control Technology To Safeguard Your Cell Therapy 2/6/2026

    The most common contamination risks in cell therapy manufacturing are open processes that leverage different products, inflexible instruments, labor intensive workflows, lack of in-line monitoring, and zero failure tolerance.

  10. Integrated Upstream And Downstream Strategies For Robust Manufacturing 2/5/2026

    Process robust mAb production requires understanding scale dependent cell environments, leveraging predictive models, and pursuing data driven control to minimize variability and optimize quality.